PulseSight

The company's core technology is a minimally invasive delivery platform that uses electro-transfection to introduce DNA plasmids encoding therapeutic proteins into the ciliary muscle. This turns the muscle cells into biofactories that produce and deliver therapeutic proteins to the retina over an extended period, with demonstrated clinical benefits lasting up to eight months from a single administration. This platform has been clinically validated for safety in a prior Phase I/II study for uveitis. The business model focuses on advancing its drug candidates through clinical trials to address the significant unmet needs in the ophthalmology market, which is estimated to reach $27.5 billion by 2031. PulseSight secures capital through venture funding, having raised $54.2M over several rounds and completing the first close of a Series A financing in February 2025 to fund clinical development.

PulseSight's pipeline targets age-related macular degeneration (AMD), which affects 200 million people globally. Its lead program, PST-809, is being developed for wet AMD and uses a dual-gene plasmid that expresses both aflibercept (a potent anti-VEGF) and decorin (an anti-angiogenic and anti-fibrotic protein). This approach aims to reduce vascular leakage and subretinal fibrosis, potentially requiring re-treatment only every six months. A second program, PST-611, targets Geographic Atrophy (GA), the late stage of dry AMD. PST-611 delivers a plasmid that encodes for human transferrin to regulate iron levels, which in turn reduces oxidative stress and prevents retinal degeneration. A Phase 1 clinical trial for PST-611 began in the summer of 2025. This candidate has also received orphan drug designation from the FDA and EMA for other neurodegenerative retinal disorders.